Phacilitate announces the return of Advanced Therapies Week (ATW) for its 22nd year, reinforcing its status as one of the most established and influential cell and gene therapy (CGT) conferences in the United States and among the most recognized globally.
- In its 22nd year, Advanced Therapies Week continues to bring together the cell and gene therapy (CGT) community to make progress possible
- The 2026 Innovation Zone will showcase emerging technologies and breakthroughs
- Investment Summit, integrated content stages, Special Interest Groups and expanded networking experiences demonstrate the growing scale of this influential US conference
- Exhibitors reflect advanced therapies ecosystem
Advanced Therapies Week 2026 is expected to attract more than 2,000 attendees from biotech, pharma, CDMO, and investment professionals, with over 600 CGT developers and 250 speakers, positioning it as one of the largest and most comprehensive gatherings in the field. The 2026 event will take place from February 9-12, 2026, at the San Diego Convention Center in San Diego, California. ATW’s new venue is strategically placed in one of the world’s most dynamic biotech hubs between academia, industry, and investment.
Kimberley Barnes, President at Phacilitate, says:
“Advanced Therapies Week, now in its 22nd year, is where conversations turn into partnerships, where ideas become strategies, and where connections lead to lasting impact. This event will play a critical role in helping to shape the next decade of advanced therapies.
“As the cell and gene therapy field enters a new phase marked by rapid scientific maturation, rising regulatory complexity and the need for scalable manufacturing, Advanced Therapies Week remains focused on its core purpose: bringing the cell and gene therapy community together to make progress possible. Partnerships form when people are in the room together and our role at Phacilitate is to create a space where those connections, scientific, strategic and human, can thrive.”
Innovation, investment, communication
Advanced Therapies Week 2026 will feature the enhanced Innovation Zone, a dedicated space designed to showcase emerging technologies and highlight the people behind these breakthroughs. It will take center stage at the heart of the conference, creating an opportunity for exhibitors to communicate their value to investors and established industry players.
The 2026 program also features the Investment Summit, integrated content stages, Special Interest Groups and expanded networking experiences including a range of social gatherings – from the Welcome Party to the Petco Park stadium takeover – all engineered to encourage conversation, not just attendance.
The importance of communication also shapes the event’s scientific program. Leaders from companies whose influence extends across the global CGT landscape, including Novartis and Bayer, will be present at Advanced Therapies Week 2026. Their participation will not focus solely on presenting data but will openly discuss challenges, share experiences, and offer guidance that can help the wider field advance with greater coordination and clarity.
Exhibitors reflect advanced therapies ecosystem
A strong cohort of exhibitors are confirmed spanning manufacturing, automation, logistics, and enabling technologies, demonstrating the event’s role as a central meeting point for the full advanced therapies ecosystem.
Companies exhibiting include AGC Biologics, Adva Biotechnology, Bausch+Ströbel in partnership with KyooBe Tech, BBG Advanced Therapies, BioLife Solutions, Cardinal Health, Catalent, Cellares, Charles River, Consort, Corning Life Sciences, Cryoport, Cytiva, Danaher, Dark Horse Consulting, ElevateBio, Emerson, Fresenius Kabi, Fujifilm, Genezen, Gift of Life, Kincell Bio, Lonza AG, Nucleus Biologics, Resilience, Roslin CT, Sartorius, Thermo Fisher Scientific and Viralgen.
Registration and exhibitor opportunities for Advanced Therapies Week 2026 are open. To be part of the connections shaping the future of cell and gene therapy, visit Advanced Therapies Week 2026 Registration.
